WHO ICTRP trial
FOLFIRI plus cetuximab as first-line therapy followed by cetuximab maintenance…
ChiCTR1900026360 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR1900026360 |
|---|---|
| Public title | FOLFIRI plus cetuximab as first-line therapy followed by cetuximab maintenance therapy in patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer: a single institute study |
| Scientific title | FOLFIRI plus cetuximab as first-line therapy followed by cetuximab maintenance therapy in patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer: a single institute study |
| Primary sponsor | Medical Oncology Fujian Medical University Union Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | 0 |
| Countries | China |
| Conditions | Colorectal Cancer |
| Interventions | Experimental group:cetuximab 500 mg/m2 d1, combined with irinotecan 180 mg/m2 d1, intravenous drip 90 min d1, every 2 weeks as a cycle, record the disease control. In the maintenance phase1 group, if reach disease control (PR, CR, SD) after… |
| Registration date | Oct 2, 2019 |
| Target size | Experimental group:30;Control group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: